Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy a systematic review

Circulation: Cardiovascular Imaging

Volumn 6, Issue 6, 2013, Pages 1080-1091

  Thavendiranathan, Paaladinesh ^a   Wintersperger, Bernd J ^a   Flamm, Scott D ^b   Marwick, Thomas H ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Cancer chemotherapy agents; Cardiac; Edema; Heart failure; Left; Magnetic resonance imaging; Toxicity; Ventricular function

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; GADOLINIUM; TRASTUZUMAB;

ARTERIAL STIFFNESS; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CARDIOVASCULAR MAGNETIC RESONANCE; CONTRAST ENHANCEMENT; HEART EDEMA; HEART INJURY; HEART LEFT VENTRICLE MASS; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE FUNCTION; HEART VENTRICLE VOLUME; HUMAN; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; MYOCARDIAL DISEASE; MYOCARDIAL EDEMA; MYOCARDITIS; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; SYSTOLE; TREATMENT RESPONSE;

CANCER CHEMOTHERAPY AGENTS; EDEMA, CARDIAC; HEART FAILURE; MAGNETIC RESONANCE IMAGING; TOXICITY; VENTRICULAR FUNCTION, LEFT;

ANTINEOPLASTIC AGENTS; HEART DISEASES; HUMANS; MAGNETIC RESONANCE IMAGING, CINE; NEOPLASMS; RISK FACTORS;

EID: 84892144673     PISSN: 19419651     EISSN: 19420080     Source Type: Journal    
DOI: 10.1161/CIRCIMAGING.113.000899     Document Type: Review

References (55)

1. American Cancer Society. Cancer Facts & Figure 2013. Atlanta, GA: American Cancer Society; 2013. http://www.cancer.org/acs/groups/content/ @epidemiologysurveilance/documents/document/acspc-036845.pdf. Accesed May 21, 2013.
2. Chen J, Long JB, Hurria A, Owusu C., Steingart RM, Gross CP Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol. 2012; 60:2504-2512.
3. Patnaik JL, Byers T, DiGuiseppi C., Dabelea D, Denberg TD Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res. 2011; 13:R64.
4. Yeh ET, Bickford CL Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009; 53:2231-2247.
5. Wadhwa D, Fallah-Rad N, Grenier D., Krahn M, Fang T, Ahmadie R., Walker JR, Lister D, Arora RC, Barac I, Morris A., Jassal DS Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study. Breast Cancer Res Treat. 2009; 117:357-364.
6. Vasu S, Hundley WG Understanding cardiovascular injury after treatment for cancer: an overview of current uses and future directions of cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2013; 15:66.
7. Bristow MR, Thompson PD, Martin R.P., Mason JW, Billingham ME, Harrison DC Early anthracycline cardiotoxicity. Am J Med. 1978; 65:823-832.
8. Riad A, Bien S, Westermann D., Becher PM, Loya K, Landmesser U, Kroemer H.K., Schultheiss HP, Tschöpe C. Pretreatment with statin attenuates the cardiotoxicity of Doxorubicin in mice. Cancer Res. 2009; 69:695-699.
9. Kajihara H, Yokozaki H, Yamahara M., Kadomoto Y, Tahara E. Anthracycline induced myocardial damage. An analysis of 16 autopsy cases. Pathol Res Pract. 1986; 181:434-441.
10. Billingham ME, Mason JW, Bristow M.R., Daniels JR Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep. 1978; 62:865-872.
11. Friedman MA, Bozdech MJ, Billingham M.E., Rider AK Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals. JAMA. 1978; 240:1603-1606.
12. Mason JW, Bristow MR, Billingham M.E., Daniels JR Invasive and non-invasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat Rep. 1978; 62:857-864.
13. Cottin Y, Ribuot C, Maupoil V., Godin D, Arnould L, Brunotte F., Rochette L. Early incidence of adriamycin treatment on cardiac parameters in the rat. Can J Physiol Pharmacol. 1994; 72:140-145.
14. Bernaba BN, Chan JB, Lai C.K., Fishbein MC Pathology of late-onset anthracycline cardiomyopathy. Cardiovasc Pathol. 2010; 19:308-311.
15. Fallah-Rad N., Walker JR, Wassef A, Lytwyn M., Bohonis S, Fang T, Tian G., Kirkpatrick ID, Singal PK, Krahn M, Grenier D., Jassal DS The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol. 2011; 57:2263-2270.
16. Felker GM, Thompson RE, Hare J.M., Hruban RH, Clemetson DE, Howard DL, Baughman K.L., Kasper EK Underlying causes and longterm survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000; 342:1077-1084.
17. Jessup M, Abraham WT, Casey D.E., Feldman AM, Francis GS, Ganiats TG, Konstam M.A., Mancini DM, Rahko PS, Silver MA, Stevenson L.W., Yancy CW 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009; 119:1977-2016.
18. Seidman A, Hudis C, Pierri M.K., Shak S., Paton V, Ashby M, Murphy M., Stewart SJ, Keefe D. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002; 20:1215-1221.
19. Armstrong GT, Plana JC, Zhang N, Srivastava D., Green DM, Ness KK, Daniel Donovan F, Metzger ML, Arevalo A, Durand J.B., Joshi V., Hudson MM, Robison LL, Flamm SD Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol. 2012; 30:2876-2884.
20. Swain SM, Whaley FS, Ewer MS Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003; 97:2869-2879.
21. Oreto L, Todaro MC, Umland M.M., Kramer C., Qamar R, Carerj S, Khandheria B.K., Paterick TE Use of echocardiography to evaluate the cardiac effects of therapies used in cancer treatment: what do we know? J Am Soc Echocardiogr. 2012; 25:1141-1152.
22. Negishi K, Negishi T, Hare J.L., Haluska BA, Plana JC, Marwick TH Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr. 2013; 26:493-498.
23. Cardinale D, Sandri MT, Martinoni A, Borghini E., Civelli M, Lamantia G, Cinieri S., Martinelli G, Fiorentini C, Cipolla CM Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol. 2002; 13:710-715.
24. Cardinale D, Colombo A, Torrisi R., Sandri MT, Civelli M, Salvatici M, Lamantia G., Colombo N, Cortinovis S, Dessanai M.A., Nolè F, Veglia F, Cipolla CM. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010; 28:3910-3916.
25. Grothues F, Smith GC, Moon J.C., Bellenger NG, Collins P, Klein HU, Pennell DJ Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol. 2002; 90:29-34.
26. Sandner TA, Houck P, Runge V.M., Sincleair S., Huber AM, Theisen D, Reiser MF, Wintersperger BJ Accuracy of accelerated cine MR imaging at 3 Tesla in longitudinal follow-up of cardiac function. Eur Radiol. 2008; 18:2095-2101.
27. Lightfoot JC, D'Agostino RB Jr, Hamilton CA, Jordan J, Torti FM, Kock ND, Jordan J, Workman S, Hundley WG. Novel approach to early detection of doxorubicin cardiotoxicity by gadolinium-enhanced cardiovascular magnetic resonance imaging in an experimental model. Circ Cardiovasc Imaging. 2010; 3:550-558.
28. Liberati A, Altman DG, Tetzlaff J, Mulrow C., Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339:b2700.
29. Drafts BC, Twomley KM, D'Agostino R Jr, Lawrence J, Avis N, Ellis LR, Thohan V, Jordan J, Melin SA, Torti FM, Little WC, Hamilton CA, Hundley WG. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of sub-clinical cardiovascular disease. J Am Coll Cardiol Cardiovasc Imaging. 2013; 6:877-885.
30. Lunning MA, Kutty S, Rome E.T., Li L., Padiyath A, Loberiza F, Bociek R.G., Bierman PJ, Vose JM, Armitage JO, Porter TR Cardiac magnetic resonance imaging for the assessment of the myocadium following doxorubicin-based chemotherapy. Am J Clin Oncol. July 2, 2013; doi: 10.1097/COC.0b013e31829e19be: http://journals.lww.com/amjclini-caloncology. Accessed November 1, 2013.
31. Ylänen K., Poutanen T, Savikurki-Heikkilä P, Rinta-Kiikka I, Eerola A, Vettenranta K. Cardiac magnetic resonance imaging in the evaluation of the late effects of anthracyclines among long-term survivors of childhood cancer. J Am Coll Cardiol. 2013; 61:1539-1547.
32. Neilan TG, Coelho-Filho OR, Pena-Herrera D, Shah R.V., Jerosch-Herold M, Francis SA, Moslehi J, Kwong RY Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines. Am J Cardiol. 2012; 110:1679-1686.
33. Chaosuwannakit N, D'Agostino R Jr, Hamilton CA, Lane KS, Ntim WO, Lawrence J, Melin SA, Ellis LR, Torti FM, Little WC, Hundley WG. Aortic stiffness increases upon receipt of anthracycline chemotherapy. J Clin Oncol. 2010; 28:166-172.
34. Oberholzer K, Kunz RP, Dittrich M, Thelen M. [Anthracycline-induced cardiotoxicity: cardiac MRI after treatment for childhood cancer]. Rofo. 2004; 176:1245-1250.
35. Wassmuth R, Lentzsch S, Erdbruegger U., Schulz-Menger J, Doerken B, Dietz R., Friedrich MG Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging-a pilot study. Am Heart J. 2001; 141:1007-1013.
36. Hundley WG. Mri in detecting heart damage in patients with cancer receiving chemotherapy. http://clinicaltrials.gov/show/NCT01719562. Accessed April 2, 2013.
37. Hare J. Use of myocardial tissue characterization by cardiac magentic resonance imaging to predict left ventricular dysfunction in patients undergoing anthracycline chemotherapy. http://www.anzctr.org.au/ACTRN12612001100886.aspx. Accessed April 8, 2013.
38. Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G., Alakija P, Cooper LT, White J.A., Abdel-Aty H, Gutberlet M, Prasad S., Aletras A, Laissy JP, Paterson I, Filipchuk N.G., Kumar A., Pauschinger M, Liu P; International Consensus Group on Cardiovascular Magnetic Resonance in Myocarditis. Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. J Am Coll Cardiol. 2009; 53:1475-1487.
39. Ugander M, Bagi PS, Oki A.J., Chen B., Hsu LY, Aletras AH, Shah S, Greiser A., Kellman P, Arai AE Myocardial edema as detected by pre-contrast T1 and T2 CMR delineates area at risk associated with acute myocardial infarction. J Am Coll Cardiol Cardiovasc Imaging. 2012; 5:596-603.
40. Thompson RC, Canby RC, Lojeski E.W., Ratner AV, Fallon JT, Pohost GM Adriamycin cardiotoxicity and proton nuclear magnetic resonance relaxation properties. Am Heart J. 1987; 113:1444-1449.
41. Brezden-Masley C. Assessment of cardiotoxicity by cardiac magnetic resonance (cmr) in breast cancer patients receiving trastuzumab. http://clinicaltrials.gov/show/NCT01022086. Accessed April 4, 2013.
42. Stirrat J, White JA The prognostic role of late gadolinium enhancement magnetic resonance imaging in patients with cardiomyopathy. Can J Cardiol. 2013; 29:329-336.
43. Fallah-Rad N., Lytwyn M, Fang T., Kirkpatrick I, Jassal DS Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy. J Cardiovasc Magn Reson. 2008; 10:5.
44. Lawley C, Wainwright C, Segelov E., Lynch J, Beith J, McCrohon J. Pilot study evaluating the role of cardiac magnetic resonance imaging in monitoring adjuvant trastuzumab therapy for breast cancer. Asia Pac J Clin Oncol. 2012; 8:95-100.
45. Switsers O. Early detection of cardiac toxicity of trastuzumab (herceptin) in patients treated for breast carcinoma: value of magnetic resonance imaging (mrtox). http://clinicaltrials.gov/show/NCT01436604. Accessed April 9, 2013.
46. Sutton-Tyrrell K., Najjar SS, Boudreau R.M., Venkitachalam L., Kupelian V, Simonsick EM, Havlik R, Lakatta E.G., Spurgeon H., Kritchevsky S, Pahor M, Bauer D., Newman A; Health ABC Study. Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults. Circulation. 2005; 111:3384-3390.
47. Castellino SM. Rithm-resonance imaging trial for heart biomarkers in adolescent/young (aya) cancer survivors. http://clinicaltrials.gov/ct2/show/ NCT01719094. Accessed May 31, 2013.
48. Unverferth DV, Fetters JK, Unverferth B.J., Leier CV, Magorien RD, Arn AR, Baker PB Human myocardial histologic characteristics in congestive heart failure. Circulation. 1983; 68:1194-1200.
49. Ugander M, Oki AJ, Hsu L.Y., Kellman P., Greiser A, Aletras AH, Sibley C.T., Chen MY, Bandettini WP, Arai AE Extracellular Volume imaging by magnetic resonance imaging provides insights into overt and sub-clinical myocardial pathology. Eur Heart J. 2012; 33:1268-1278.
50. Tham EB, Haykowsky MJ, Chow K, Spavor M., Kaneko S, Khoo NS, Pagano J.J., Mackie AS, Thompson RB Diffuse myocardial fibrosis by T1-mapping in children with subclinical anthracycline cardiotoxic-ity: relationship to exercise capacity, cumulative dose and remodeling. J Cardiovasc Magn Reson. 2013; 15:48.
51. Neilan TG, Coelho-Filho OR, Shah R.V., Feng JH, Pena-Herrera D, Mandry D, Pierre-Mongeon F, Heydari B., Francis SA, Moslehi J, Kwong RY, Jerosch-Herold M. Myocardial extracellular Volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy. Am J Cardiol. 2013; 111:717-722.
52. Bosch X, Rovira M, Sitges M., Domènech A, Ortiz-Pérez JT, de Caralt TM, Morales-Ruiz M, Perea RJ, Monzó M, Esteve J. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol. 2013; 61:2355-2362.
53. Pituskin E, Haykowsky M, Mackey J.R., Thompson RB, Ezekowitz J, Koshman S, Oudit G., Chow K, Pagano JJ, Paterson I. Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101-Breast): a randomized, placebo-controlled trial to determine if conventional heart failure phar-macotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI. BMC Cancer. 2011; 11:318.
54. Heck SL, Gulati G, Ree A.H., Schulz-Menger J, Gravdehaug B, Røsjø H, Steine K, Bratland A, Hoffmann P, Geisler J, Omland T. Rationale and design of the prevention of cardiac dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial. Cardiology. 2012; 123:240-247.
55. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992; 327:685-691.